Issue 42, 2023

NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy

Abstract

An NQO1-responsive precursor, named R848-QPA, has been developed to evoke an anti-tumor immune response. R848-QPA can induce innate immune activation when activated by overexpressed NQO1 in the tumor microenvironment while showing lower activity in NQO1-deprived environments. This strategy provides a new method for the development of tumor-microenvironment-responsive prodrugs for antitumor immunotherapy.

Graphical abstract: NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy

Supplementary files

Article information

Article type
Communication
Submitted
13 Feb 2023
Accepted
26 Apr 2023
First published
27 Apr 2023

Chem. Commun., 2023,59, 6343-6346

NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy

G. Li, Y. Xu, X. Kong, L. Gu, Y. Qin and L. Wu, Chem. Commun., 2023, 59, 6343 DOI: 10.1039/D3CC00663H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements